Literature DB >> 29415639

Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients.

Ming Ma1, Riyang Zhao2, Xingxiao Yang3, Lianmei Zhao2, Lihua Liu4, Cong Zhang2, Xuexiao Wang4, Baoen Shan2.   

Abstract

Objectives Burkitt lymphoma is one of the most common types of haematopoietic malignancy in children and adolescents. Mda-7/IL-24 had been identified as a differentiation inducer of Burkitt lymphoma cells. Previous studies have revealed that knockdown of C-myb can also lead to the terminal differentiation of Burkitt lymphoma cells. The aim of the present study was to investigate the correlation between the expression of Mda-7/IL-24 and C-myb, as well as their prognostic significance, for Burkitt lymphoma patients. Methods The tumour tissues were collected from 59 cases of Burkitt lymphoma patients and detected with Western blotting and immunohistochemistry. Results The results showed that the expression of Mda-7/IL-24 was lower, whereas the expression of C-myb was higher in Burkitt lymphoma tissues compared to specimens of normal lymph node tissues. Furthermore, C-myb expression was negatively correlated with Mda-7/IL-24 expression at the protein level in Burkitt lymphoma tissues and cell lines. Both the expression of Mda-7/IL-24 and C-myb in Burkitt lymphoma tissues was associated with some clinicopathological parameters, such as clinical stage, infiltration in the bone marrow, Ki67 and overall survival rates. Conclusion These results indicated that low expression of Mda-7/IL-24 along with high expression of C-myb are predictors for poor prognosis of Burkitt lymphoma patients; this outcome suggests that Mda-7/IL-24 and C-myb might be potential targets for clinical treatment of Burkitt lymphoma. ABBREVIATIONS: Mda-7/IL-24: melanoma differentiation associated gene7/interleukin 24; FCM: flow cytometry; Ecog: Eastern Cooperative Oncology Group; IPI: International lymphoma prognosis index.

Entities:  

Keywords:  Burkitt lymphoma; C-myb; Mda-7/IL-24; prognosis

Mesh:

Substances:

Year:  2018        PMID: 29415639     DOI: 10.1080/10245332.2018.1435046

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  6 in total

1.  c-Myb promotes growth and metastasis of colorectal cancer through c-fos-induced epithelial-mesenchymal transition.

Authors:  Xiao Qu; Xuebing Yan; Cheng Kong; Yin Zhu; Hao Li; Dengdeng Pan; Xiaohui Zhang; Yongqiang Liu; Fang Yin; Huanlong Qin
Journal:  Cancer Sci       Date:  2019-08-13       Impact factor: 6.716

2.  Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis.

Authors:  Xue-Yan Zhang; Yun-Feng Li; He Ma; Yun-He Gao
Journal:  Sci Rep       Date:  2020-04-23       Impact factor: 4.379

3.  Interleukin-24 Regulates T Cell Activity in Patients With Colorectal Adenocarcinoma.

Authors:  Yang Zhang; Ye Liu; Yuechao Xu
Journal:  Front Oncol       Date:  2019-12-10       Impact factor: 6.244

4.  DDX41 regulates the expression and alternative splicing of genes involved in tumorigenesis and immune response.

Authors:  Kai Qin; Danni Jian; Yaqiang Xue; Yi Cheng; Peng Zhang; Yaxun Wei; Jing Zhang; Huihua Xiong; Yi Zhang; Xianglin Yuan
Journal:  Oncol Rep       Date:  2021-01-25       Impact factor: 3.906

5.  IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence.

Authors:  Qian Hu; Yuxuan Zhang; Peiyun Wang; Miaojin Zhou; Zhiqing Hu; Cong Liu; Mujun Liu; Lingqian Wu; Xionghao Liu; Desheng Liang
Journal:  Signal Transduct Target Ther       Date:  2021-01-14

Review 6.  Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.

Authors:  Luni Emdad; Praveen Bhoopathi; Sarmistha Talukdar; Anjan K Pradhan; Devanand Sarkar; Xiang-Yang Wang; Swadesh K Das; Paul B Fisher
Journal:  Semin Cancer Biol       Date:  2019-07-26       Impact factor: 15.707

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.